Dartmouth and Aeras join forces to conduct study of new tuberculosis vaccine

March 19, 2014

Dartmouth's Geisel School of Medicine and Aeras, a global nonprofit biotech, announced a collaboration to jointly conduct a trial of a new vaccine against tuberculosis (TB), one of the world's deadliest diseases. The vaccine, known as DAR-901, is related to the vaccine SRL-172, previously shown by Dartmouth investigators to decrease the risk of TB in a trial known as the DarDar Trial.

In the announcement today Aeras indicated that DAR-901 will now be added to Aeras's portfolio of TB vaccines in . Dr. Tom Evans, Aeras President & CEO said, "The world desperately needs new vaccines to prevent the global spread of TB. We are pleased to join forces with Dartmouth's Dr. Ford von Reyn and the DAR-901 partners in manufacturing the candidate and supporting the first clinical trial."

Professor Ajit Lalvani, director of the Tuberculosis Research Centre, National Heart and Lung Institute at Imperial College London, commented "It's heartening to see Aeras and Dartmouth join forces to advance this vaccine candidate. Its precursor —SRL-172—is the only new vaccine to have shown evidence of protection against TB in humans and in particular in HIV-infected persons, the most vulnerable group. This is an important step forward in the global battle against TB."

The previous study of the related SRL-172, known as the DarDar Trial, was a 7-year, randomized, controlled trial among 2,000 HIV-infected patients in Tanzania. The DarDar Trial demonstrated that the new vaccine was safe and 39 percent effective in preventing definite TB in HIV-infected adults with a CD4 cell count of at least 200 cells/ml.

DAR-901 will be evaluated as a booster vaccine for adolescents and adults throughout the world who received the existing and widely used Bacille Calmette-Guérin (BCG) TB vaccine as infants or young children. BCG has been shown to prevent some forms of TB, but its widespread use in infants has failed to control the global epidemic. DAR-901 is an inactivated form of an entire bacterial organism closely related to M. , the bacterium that causes TB; it is thought to stimulate the type of broad immune response that may be necessary for prevention of TB in humans.

"The DarDar Trial is the only double-blind, randomized, controlled trial of a new TB vaccine to have demonstrated evidence of efficacy in humans," said Dr. Ford von Reyn, Professor of Medicine at Dartmouth's Geisel School of Medicine and principal investigator. "We are very pleased to be moving forward with the development of the closely related vaccine, DAR-901, and thankful for Aeras's . Our goal is to demonstrate that this is an effective booster vaccine that could help reduce the burden of TB disease throughout the world."

Each year, more than 8.5 million people develop active TB and 1.3 million people die of the disease. TB is also the leading cause of death among people living with HIV. The Dartmouth team has been focused on research to combat TB since von Reyn's tenure with the World Health Organization's AIDS program in 1987.

Based on the results of the DarDar trial, Dartmouth investigators engaged Aeras to develop a scalable method for manufacturing for the vaccine. Using the new approach, millions of doses of the , now designated DAR-901, can be produced at low cost. An Investigational New Drug application (IND) for DAR-901 has been accepted by the U.S. Food and Drug Administration. The Phase I study of DAR-901 will be initiated at Dartmouth later this spring.

Explore further: Dartmouth medical research closes in on new tuberculosis vaccine

Related Stories

Dartmouth medical research closes in on new tuberculosis vaccine

August 23, 2012
Tuberculosis (TB) is second only to HIV/AIDS as the greatest killer worldwide attributable to a single infectious agent, according to the World Health Organization (WHO). With 8.8 million cases in 2010 and 95 percent of TB ...

BCG vaccine more effective than previously thought

December 19, 2013
The BCG vaccine has been found to be more effective against the most common form of tuberculosis than previously thought, according to a new study in Clinical Infectious Diseases.

New tuberculosis vaccine doesn't protect infants, study finds

February 4, 2013
The world's most advanced tuberculosis vaccine failed to protect babies against the infectious disease, according to a new study in South Africa.

Final child vaccinated in clinical trial of new TB vaccine

May 4, 2011
The final participant in a clinical trial to assess the safety and efficacy of a new vaccine against tuberculosis (TB) has been vaccinated.

Recommended for you

Two lung diseases killed 3.6 million in 2015: study

August 17, 2017
The two most common chronic lung diseases claimed 3.6 million lives worldwide in 2015, according to a tally published Thursday in The Lancet Respiratory Medicine.

New test differentiates between Lyme disease, similar illness

August 16, 2017
Lyme disease is the most commonly reported vector-borne illness in the United States. But it can be confused with similar conditions, including Southern Tick-Associated Rash Illness. A team of researchers led by Colorado ...

Addressing superbug resistance with phage therapy

August 16, 2017
International research involving a Monash biologist shows that bacteriophage therapy – a process whereby bacterial viruses attack and destroy specific strains of bacteria - can be used successfully to treat systemic, multidrug ...

Can previous exposure to west Nile alter the course of Zika?

August 15, 2017
West Nile virus is no stranger to the U.S.-Mexico border; thousands of people in the region have contracted the mosquito-borne virus in the past. But could this previous exposure affect how intensely Zika sickens someone ...

Compounds in desert creosote bush could treat giardia and 'brain-eating' amoeba infections

August 15, 2017
Researchers at Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego and the University of Colorado Anschutz Medical Campus have found that compounds produced by the creosote bush, a ...

New malaria analysis method reveals disease severity in minutes

August 11, 2017
Left untreated, malaria can progress from being mild to severe—and potentially fatal—in 24 hours. So researchers at the University of British Columbia developed a method to quickly and sensitively assess the progression ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.